SCHEMBL3004540

SCHEMBL3004540

CCOc1ccc(Cc2csc(N3CCC(S(=O)(=O)c4cc(Cl)ccc4Cl)CC3)n2)cc1

nearest known ligand 0.40

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 3/20 0.40
TDP1 Q9NUW8 1/20 0.39
PTGDR2 Q9Y5Y4 3/20 0.39
MAPT P10636 5/20 0.39
TSHR P16473 2/20 0.38
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
POLB P06746 1/20 0.37
TP53 P04637 1/20 0.36
SMN1; SMN2 Q16637 3/20 0.36
GAA P10253 2/20 0.36
NPSR1 Q6W5P4 1/20 0.35
LMNA P02545 2/20 0.35
MAPK14 Q16539 1/20 0.35
KDM4E B2RXH2 1/20 0.35
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3009850 0.93 CNR2 (0.41) CNR2TDP1PTGDR2MAPTTP53
SCHEMBL2999661 0.91 MAPT (0.40) MAPTTSHRMEN1KMT2APOLB
SCHEMBL3017048 0.91 LMNA (0.44) CNR2MAPTTSHRMEN1KMT2A
SCHEMBL3021640 0.90 ACHE (0.36) MAPTTSHRMEN1KMT2APOLB
SCHEMBL3012479 0.90 MAPT (0.39) TDP1MAPTTSHRKMT2APOLB
SCHEMBL3006934 0.90 CTSS (0.42) CNR2TDP1MAPTMEN1KMT2A
SCHEMBL3007437 0.90 CNR2 (0.38) CNR2TDP1TSHRMEN1KMT2A
SCHEMBL15671712 0.89 CNR2 (0.41) CNR2TDP1PTGDR2MAPTKMT2A
SCHEMBL3004810 0.89 TSHR (0.35) MAPTTSHRMEN1KMT2APOLB
SCHEMBL3008794 0.89 MAPT (0.46) TDP1MAPTTSHRMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA CNR2 2911/4885TDP1 86/4885PTGDR2 2676/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.